logo-loader

AstraZeneca reports positive results from trial of pancreatic cancer treatment

Published: 08:35 03 Jun 2019 BST

Pancreatic
In 2018, there were 458,918 new cases of pancreatic cancer worldwide

AstraZeneca PLC (LON:AZN) said its Lynparza treatment nearly doubled the life-span of patients with metastatic pancreatic cancer in a phase III trial.

The trial tested Lynparza tablets as an initial maintenance treatment for metastatic pancreatic cancer patients, whose disease had not progressed after chemotherapy.

READ: AstraZeneca gets US regulatory green light for slow-release diabetes drug

Results showed “statistically significant and clinically meaningful improvement” in the time patients could live without their disease getting worse by an average of 7.4 months on Lynparza, compared to 3.8 months for those on placebo.

More than twice as many patients showed no disease progression both at one year and two years after starting to take Lynparza.  

José Baselga, executive vice president of oncology research and development, said: "These unprecedented results raise new hope for patients that have seen little progress over a long period of time.”

He said AstraZeneca is now working with regulatory authorities to bring Lynparza to patients “as quickly as possible”.

Pancreatic cancer has the worst survival rate of the most common cancers with less than 3% of patients surviving more than five years after diagnosis.

Early diagnosis of pancreatic cancer is difficult because there are usually no symptoms until it is too late.  About 80% of patients are diagnosed at the metastatic stage.

In 2018, there were 458,918 new cases of pancreatic cancer worldwide.

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

2 hours, 35 minutes ago